Drug Trial Radar · NCT01035255
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Last checked: Nov 19, 2026Latest source record: Aug 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8,442
Actual
Start
Dec 2009
Primary completion
May 2014
Study completion May 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696 200 mg BIDDrug
LCZ696 200 mg BID
Enalapril 10 mg BIDDrug
Enalapril 10 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationTime frame: up to 51 months
Locations
1,031 sites in 47 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Muscle Shoals, Alabama
Novartis Investigative Site
Anchorage, Alaska
Novartis Investigative Site
Gilbert, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Bellflower, California
Novartis Investigative Site
Berkley, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Mather, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Palm Springs, California
Novartis Investigative Site
Pomona, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Santa Rosa, California
Novartis Investigative Site
Stockton, California
Novartis Investigative Site
Tustin, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Stamford, Connecticut
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Boynton Beach, Florida
Novartis Investigative Site
Davie, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Lakeland, Florida
Novartis Investigative Site
Leesburg, Florida
Showing 40 of 1,031 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.